PHI Management
Board of Directors
Goran Dubravčić (Chairman of the Board, born 1979) is the CEO of Altium SA. Altium is a private investment company based in Switzerland with a rich history of success, growth, and stability. As an international distributors company network, Altium delivers targeted and efficient solutions to various markets, including life science and chemical analysis.
Petter Björquist (Board Member, born 1965) joined Cellartis as VP of Regenerative Medicine soon after it was founded in 2001. Since its foundation, Cellartis (now Takara Bio Europe AB) has continued to provide embryonic stem cell cultures for regenerative medicine applications. Petter is currently the CEO of VERIGRAFT AB. Verigraft generates personalized tissue-engineered transplants for use in regenerative medicine. He also serves on the board of Stimuliver ApS, a Copenhagen biotech firm specializing in cell therapies for liver diseases, and ATMP Sweden, a leading network in Swedish regenerative medicine. Additionally, he advises the global organization Alliance for Regenerative Medicine (ARM).
Mats Lundwall (Board Member, born 1948) has a comprehensive and successful international career, with many years of overseas experience in the pharmaceutical and biotechnology sectors, predominantly in vital CEO roles. As CEO, he significantly contributed to Ferring Pharmaceuticals’ international growth and the consolidation of its global operations. Throughout the years, he has been instrumental in various transactions, forming a prominent international group spanning pharmaceutical, chemical, and diagnostic businesses (Nordic Drugs, Q-Pharma, Eurodiagnostica, Polypeptide). Moreover, he served as the CEO of Santaris Pharma A/S and Cellartis AB, both venture capital-backed companies, which were successfully developed and subsequently sold. Mats has held, and continues to hold, numerous board positions in the international sector, both as a member and as a chairman.
John Moore (Board Member, born 1965) is an active investor and entrepreneur in the life science and energy industries. He currently serves as Chairman of two public life science companies, Nyrada (NYR-ASX) and Scientific Industries (SCND-OTCQB), and two private companies, Trialogics, a clinical trial software business and Cormetech, a leading carbon capture business.
Ivan Jurkovic (Board member, born 1984) is an experienced financial executive with experience in the pharmaceutical industry, beverage industry and IT industry. Mr Jurkovic currently holds the position of Chief Financial Officer at Altium SA. As part of his role at Altium, Mr Jurkovic is responsible for Altium’s financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth. Previously, Jurkovic was an advisor to Coca-Cola Hellenic Bottling Company (12/2016 – 09/2020), where he supervised a revenue stream of over €200 million across three countries.
Peter Egelberg (Board member and founder of PHI, born 1963) has an extensive background in physics and computer engineering. Instead of relying on a microscope lens to create the image, Peter’s groundbreaking idea in 2000, which led to the foundation of PHI, was to record the light information that a computer algorithm requires to produce the image. This approach, offering several advantages, is today known as quantitative phase imaging and is set to fully replace the soon 100-year-old microscopy method commonly used to observe living cell cultures in regenerative medicine, conventional medical research and drug development.
Leland Foster (Board member, born 1946) was the former CEO of HyClone Laboratories, Inc., a pioneer and world-leading supplier of cell culture media including animal serum. Through the acquisition of Hyclone’s parent company, Perbio Science AB, where he was CEO, HyClone became part of the Fisher Scientific Biosciences Group, and he was appointed CEO of the group. With the merger of Fisher Scientific and ThermoElecton to create ThermoFisher Scientific, now among the largest global biopharma suppliers, he became Chief Scientist after the merger.
Advisor
At the merger of Thermo and Fisher, Ron Lowy (Advisor, born 1955) succeeded Leland Foster (former PHI Board member) as President and CEO of the Fisher Scientific Bioscience Group when Leland was appointed CTO of Fisher Scientific. After the merger, Ron remained in his role while Leland took the position of Chief Scientist for Thermo Fisher. Ron currently serves on the boards of several medical equipment, experimental design platforms, and drug discovery companies, including as Chairman for Magnolia Medical Technologies, a company enhancing the precision of blood culture analyses.